J. I. Moliva

This paper designs universal Ebola virus vaccine candidates using hyperglycosylation to focus antibody responses on conserved epitopes, showing cross-neutralizing activity against multiple orthoebolavirus species.

This paper develops an mRNA-lipid nanoparticle vaccine targeting four conserved MPXV surface proteins, showing superior protection against VACV compared to MVA.

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

This study compares B cell responses and protection against Omicron after boosting vaccinated macaques with mRNA-1273 or mRNA-Omicron vaccines, finding comparable immunity and protection.

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

mRNA-1273 boosted nonhuman primates show increased neutralizing antibody responses and protection against SARS-CoV-2 beta variant infection.

This study shows that mRNA-1273 vaccine-induced antibody responses correlate with protection against SARS-CoV-2 infection in nonhuman primates.

This study evaluates the neutralizing antibody response of mRNA-1273 vaccine against SARS-CoV-2 variants B.1.1.7 and B.1.351 using pseudovirus neutralization assays.

This paper develops a nanoparticle platform for displaying trimeric antigens, showing that SARS-CoV-2 spike-LuS nanoparticles induce 25-fold higher neutralizing responses than spike alone.